Coherus Oncology
CHRS
186 hedge funds and large institutions have $1.21B invested in Coherus Oncology in 2020 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 28 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 62
13% more call options, than puts
Call options by funds: $3.88M | Put options by funds: $3.45M
2.07% more ownership
Funds ownership: 103.68% → 105.75% (+2.1%)
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less funds holding
Funds holding: 188 → 186 (-2)
7% less capital invested
Capital invested by funds: $1.31B → $1.21B (-$97.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$37.3M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$34.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.4M |
| 4 |
JP Morgan Chase
New York
|
+$12.3M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$39.4M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$12.9M |
| 3 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
-$11.8M |
| 4 |
Holocene Advisors
New York
|
-$10.7M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$10M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
201
Boothbay Fund Management
New York
| – | -$222K | -12,000 | Closed |
|
202
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$209K | -11,600 | Closed |
|
|
BCM
203
Bayesian Capital Management
Brooklyn,
New York
| – | -$190K | -10,536 | Closed |
|
|
NIT
204
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$141K | -7,806 | Closed |
|
|
TRCT
205
Tower Research Capital (TRC)
New York
| – | -$134K | -7,433 | Closed |
|
|
HI
206
Hoey Investments
Coatesville,
Pennsylvania
| – | -$66K | -3,650 | Closed |
|
|
FIB
207
First Interstate Bank
Billings,
Montana
| – | -$16K | -871 | Closed |
|
|
OIA
208
Optimum Investment Advisors
Chicago,
Illinois
| – | -$9K | -500 | Closed |
|
|
CG
209
Cutler Group
San Francisco,
California
| – | -$5.54K | -300 | Closed |
|
|
OSAM
210
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$4K | -227 | Closed |
|
|
QT
211
Quantbot Technologies
New York
| – | -$2K | -143 | Closed |
|
CHRS Hedge Fund Activity: Q1 2020 in Review
186 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2020, worth a combined $1.21B — down 7.4% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new CHRS positions and 28 closed out — a net gain of 1 holder — while 73 added to existing stakes and 62 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $37.3M. The largest seller was Lord, Abbett & Co, cutting an estimated $39.4M.
- 186 institutional investors held Coherus Oncology (CHRS) as of Q1 2020, down from 188 in Q4 2019.
- Funds reported $1.21B of Coherus Oncology stock for Q1 2020, down 7.4% quarter-over-quarter.
- 29 funds opened new Coherus Oncology positions in Q1 2020 and 28 closed out, a net change of +1 holder.
- The largest Coherus Oncology buyer in Q1 2020 was Consonance Capital Management, an estimated $37.3M added.
- The largest Coherus Oncology seller in Q1 2020 was Lord, Abbett & Co, an estimated $39.4M sold.
Based on aggregated 13F filings for Q1 2020.